Hospital Universitario de Saltillo

Hospital Universitario de Saltillo
Calz Francisco I. Madero 1291, Zona Centro, 25000 Saltillo, Coah
Select an option
Open studies
Breast Cancer
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression - FORTITUDE-301 - AmgenSee more
Cervical cancer
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression - FORTITUDE-301 - AmgenSee more
Head and neck cancer
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression - FORTITUDE-301 - AmgenSee more
Lung cancer
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression - FORTITUDE-301 - AmgenSee more
Ovarian cancer
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression - FORTITUDE-301 - AmgenSee more
Solid tumors
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression - FORTITUDE-301 - AmgenSee more
Trialtech
About usOur missionOur teamPartnersFAQs
Medical newsLatest newsStudiesInterviewsTestimonials
ProductsUEPM OncoUEPM Physicians
LinksDownloads
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy